BTIG Maintains Buy on NeoGenomics, Lowers Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Mark Massaro has maintained a Buy rating on NeoGenomics (NASDAQ:NEO) but has reduced the price target from $25 to $21. This adjustment reflects a more conservative valuation of the company's future prospects.
December 29, 2023 | 12:19 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
BTIG analyst Mark Massaro maintains a Buy rating on NeoGenomics but lowers the price target from $25 to $21, indicating a positive yet more cautious stance on the company's valuation.
The reduction in the price target for NeoGenomics by BTIG suggests that there may be factors that could limit the stock's upside potential in the short term. However, maintaining a Buy rating indicates that the overall outlook remains positive. This could lead to a neutral short-term impact on the stock price as the market digests the mixed signals of a lower price target with a maintained Buy rating.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100